NFKB1 and gastric cancer: This modification enhances TAK1’s kinase activity, thereby activating the canonical NF-κB signaling pathway, ultimately triggering persistent inflammatory responses and driving the progression of gastric cancer (Lamb et al., 2013; Lamb et al., 2009).